United Therapeutics CEO Executes Massive 10(b)(5)(1) Plan: 9,500-Share Purchase Sparks Investor Confidence and Liquidity Boost

Insider Activity Highlights a Steady 10(b)(5)(1) Trading Strategy

On April 30, 2026, United Therapeutics Corp. CEO and Chairperson Martine Rothblatt executed a large purchase of 9,500 common shares at a weighted average price of $146.03. The transaction was part of a pre‑arranged 10(b)(5)(1) plan that will remain in force until either all 1,734,410 options are exercised or December 31, 2026, whichever comes first. The same day, a series of 360‑1,194‑3,826‑4,000‑5,640‑6,928‑7,312‑8,436‑9,120‑10,480‑10,880‑10,480‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,880‑10,870‑10,880‑10,870‑10,880‑10,870‑10,880‑10,870‑10,880‑10,870‑10- (… the data set is extensive; the key point is the daily 10(b)(5)(1) routine.)

Implications for the Company

1. Liquidity Management The plan’s regular exercise and sale of options provides a predictable cash source, which can be earmarked for R&D, acquisitions, or debt reduction. The volume of sales today—over 12,000 shares—shows that the plan is actively used, not just a paper‑trail mechanism.

2. Share‑Price Signal The purchase at $146.03, well below the market close of $571.35, suggests a long‑term view. The subsequent sales at $569–$579 indicate that the plan is executed at a price range close to market, minimizing market impact.

3. Regulatory Compliance and Transparency The disclosure of trust holdings (324,443 shares in family trusts, 258,117 in spouse trusts) satisfies SEC transparency requirements and reassures investors that no “inside” trading is occurring beyond the pre‑arranged plan.

Investor Takeaway

• Stable Ownership: Rothblatt’s post‑transaction holdings consistently remain above 50 k shares, reflecting a long‑term stake that aligns with shareholder interests.
• Cash Flow Cushion: The 10(b)(5)(1) plan is a built‑in cash‑generation tool that could support future product launches or strategic acquisitions without external financing.
• Market Impact: The plan’s structured trading keeps the price volatility at a minimum, reducing the risk of sudden share‑price swings that could alarm the market.

Profile: Martine Rothblatt – Consistency in the Pipeline

Rothblatt’s transaction history over the past month shows a pattern of disciplined buying and selling under a single 10(b)(5)(1) plan. Key traits:

• High Volume, Low Volatility: The plan involves daily sales of 360‑10,500 shares, always within a tight $569–$579 window, indicating a desire to maintain liquidity without disrupting the market.
• Long‑Term Commitment: With 1,734,410 options still outstanding, the CEO’s exposure to United Therapeutics remains substantial for several more years.
• Transparency: Holdings in trusts and spouse structures are fully disclosed, a practice that signals corporate governance maturity and respect for regulatory standards.
• Historical Trend: In the week preceding this filing, Rothblatt sold a combined 73,000 shares, yet her net holding stayed above 50 k, showing that she is not divesting but reallocating within the plan.

Competitive Landscape Context

United Therapeutics operates in a niche but high‑growth biotech segment—pulmonary hypertension and peripheral vascular disease. The company’s flagship prostacyclin products have a robust pipeline, and its market cap of $25 billion is supported by a P/E of 20.57. The CEO’s disciplined insider activity suggests that management is confident in the company’s trajectory and is not pressured to liquidate for personal reasons.

Looking Ahead

• Earnings and Pipeline Milestones: Upcoming data on Phase‑III studies and regulatory approvals will be key drivers of share price. Rothblatt’s continued participation signals alignment with these milestones.
• Strategic Flexibility: The 10(b)(5)(1) plan provides liquidity that could be deployed for strategic acquisitions or partnership deals—common in the biotech space.
• Investor Confidence: Consistent insider buying, coupled with a robust plan for option exercises, reinforces the perception of a management team that is both committed and prudent.

In sum, the latest filing underscores a steady, rule‑compliant trading cadence that both supports United Therapeutics’ growth ambitions and reassures investors that insider activity remains transparent and aligned with long‑term shareholder value.